Baxter (NYSE:BAX) managed to beat expectations on Wall Street with its 2nd-quarter results, despite a more than 36% bottom-line slide, saying longtime CEO Robert Parkinson Jr. plans to step down now that the spinout of its Baxalta pharmaceuticals division is complete. Deerfield, Ill.-based Baxter posted profits of $332 million, or 60¢ per share, on sales of […]
Baxter
UPDATE: Baxter recalls Vascu-Guard patches in FDA Class I recall
UPDATED June 5, 2015, with details from the FDA. Baxter (NYSE:BAX) said this week that it’s recalling its Vascu-Guard peripheral vascular patches packaged under 4 specific product codes. The company began notifying customers May 2. The FDA has labeled it as a Class I recall, the most serious type of recall issued by the federal watch […]
ConMed ripe for M&A | The week in medtech M&A
Analyst: ConMed ripe for M&A spree May 19, 2015 by Fink Densford ConMed, in the middle of an under-appreciated turnaround, could be poised to augment its growth via selective acquisitions, according to Leerink Partners analyst Richard Newitter. Newitter, who upgraded CNMD shares to “outperform” and boosted the price target to $64 from $60, wrote in […]